Advertisement
UK markets close in 2 hours 12 minutes

  • FTSE 100

    7,845.24
    -31.81 (-0.40%)
     

  • FTSE 250

    19,328.96
    -121.71 (-0.63%)
     

  • AIM

    743.17
    -2.12 (-0.28%)
     

  • GBP/EUR

    1.1675
    -0.0008 (-0.07%)
     

  • GBP/USD

    1.2448
    +0.0010 (+0.08%)
     

  • Bitcoin GBP

    51,959.24
    +1,996.89 (+4.00%)
     

  • CMC Crypto 200

    1,337.50
    +24.87 (+1.93%)
     

  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • CRUDE OIL

    82.23
    -0.50 (-0.60%)
     

  • GOLD FUTURES

    2,392.40
    -5.60 (-0.23%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     

  • DAX

    17,752.65
    -84.75 (-0.48%)
     

  • CAC 40

    8,027.97
    +4.71 (+0.06%)
     
Property:

11 beautiful homes with glorious garden rooms

Investing in a home with a garden room will enable you to enjoy your outside space whatever the weather

AstraZeneca R&D executive Morrison to lead cancer firm Syndax

Reuters - UK Focus

LONDON, June 15 (Reuters) - AstraZeneca (NYSE: AZN - news) 's outgoing chief medical officer and head of global late-stage drug development Briggs Morrison, whose departure from the British drugmaker was announced last week, is to head U.S. cancer firm Syndax Pharmaceuticals.

Syndax said on Monday that as its chief executive he would help take the privately owned company to the next level as it develops a drug called entinostat that modulates the immune system in the fight against tumours.

The U.S. company is already collaborating with Merck (Swiss: MER.SW - news) to evaluate entinostat in combination with Keytruda to treat lung cancer and melanoma.

Morrison's exit leaves a gap at the top of AstraZeneca's research operations. (Reporting by Ben Hirschler, editing by Louise Heavens)